Fulcrum Therapeutics (FULC) Short Interest Ratio & Short Volume → The Weight Loss Pill That Could Disrupt a $32 Billion Industry (From Behind the Markets) (Ad) Free FULC Stock Alerts $7.60 +0.06 (+0.80%) (As of 02:27 PM ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Fulcrum Therapeutics Short Interest DataCurrent Short Volume2,530,000 sharesPrevious Short Volume2,260,000 sharesChange Vs. Previous Month+11.95%Dollar Volume Sold Short$18.62 millionShort Interest Ratio / Days to Cover4.0Last Record DateApril 15, 2024Outstanding Shares62,150,000 sharesPercentage of Shares Shorted4.07%Today's Trading Volume112,228 sharesAverage Trading Volume607,663 sharesToday's Volume Vs. Average18% Short Selling Fulcrum Therapeutics ? Sign up to receive the latest short interest report for Fulcrum Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatFULC Short Interest Over TimeFULC Days to Cover Over TimeFULC Percentage of Float Shorted Over Time Ad Unstoppable Prosperity“Crash Insurance” For Your RetirementWhen it comes to retirement, everyone fears one thing… Outliving their retirement savings. You'll discover conservative, beginner-friendly options strategies which could help to cash flow your stock portfolio. Click here to register for free. Fulcrum Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/20242,530,000 shares $18.62 million +12.0%N/A4 $7.36 3/31/20242,260,000 shares $21.33 million -5.4%N/A3.4 $9.44 3/15/20242,390,000 shares $27.15 million -25.3%N/A3.4 $11.36 2/29/20243,200,000 shares $32.67 million -0.6%N/A4.5 $10.21 2/15/20243,220,000 shares $30.27 million -4.7%N/A5.1 $9.40 1/31/20243,380,000 shares $24.40 million -16.3%N/A5.5 $7.22 Get the Latest News and Ratings for FULC and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Fulcrum Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/15/20244,040,000 shares $28.68 million +10.1%N/A6.7 $7.10 12/31/20233,670,000 shares $24.77 million +10.2%N/A6.5 $6.75 12/15/20233,330,000 shares $17.95 million -18.0%N/A6.2 $5.39 11/30/20234,060,000 shares $19.49 million +9.7%N/A7.8 $4.80 11/15/20233,700,000 shares $15.47 million -6.3%N/A6.1 $4.18 10/31/20233,950,000 shares $14.38 million +1.0%N/A2 $3.64 10/15/20233,910,000 shares $15.21 million -2.7%N/A1.9 $3.89 9/30/20234,020,000 shares $17.85 million +7.5%N/A2 $4.44 9/15/20233,740,000 shares $16.79 million +5.1%N/A1.8 $4.49 8/31/20233,560,000 shares $19.69 million +30.4%N/A1.7 $5.53 8/15/20232,730,000 shares $11.55 million -22.2%N/A1.3 $4.23 7/31/20233,510,000 shares $13.41 million +0.3%N/A5 $3.82 7/15/20233,500,000 shares $12.88 million -4.1%N/A4.6 $3.68 6/30/20233,650,000 shares $12.05 million -19.3%N/A4.6 $3.30 6/15/20234,520,000 shares $13.74 million +9.4%N/A5.3 $3.04 5/31/20234,130,000 shares $11.23 million +4.8%N/A4.1 $2.72 5/15/20233,940,000 shares $14.34 million -17.6%N/A3.2 $3.64 4/30/20234,780,000 shares $11.95 million -6.6%N/A3.9 $2.50 4/15/20235,120,000 shares $12.34 million +3.6%N/A4.2 $2.41 3/31/20234,940,000 shares $14.08 million +25.1%N/A3.8 $2.85 3/15/20233,950,000 shares $15.01 million -2.5%N/A3.1 $3.80 2/28/20234,050,000 shares $24.46 million +7.7%N/A3.8 $6.04 2/15/20233,760,000 shares $48.69 million +6.2%N/A3.8 $12.95 1/31/20233,540,000 shares $44.64 million +6.6%N/A4.6 $12.61 1/15/20233,320,000 shares $45.48 million -7.3%N/A4.6 $13.70 12/30/20223,580,000 shares $26.06 million +21.0%N/A5.7 $7.28 12/15/20222,960,000 shares $16.22 million -9.2%N/A6.1 $5.48 11/30/20223,260,000 shares $22.33 million -4.4%N/A8.5 $6.85 11/15/20223,410,000 shares $24.48 million -2.0%N/A8.9 $7.18 10/31/20223,480,000 shares $19.35 million +0.6%N/A8 $5.56 10/15/20223,460,000 shares $25.95 million -3.9%N/A7.5 $7.50 9/30/20223,600,000 shares $29.12 million -7.2%N/A8.4 $8.09 9/15/20223,880,000 shares $35.31 million +13.8%N/A8.4 $9.10 8/31/20223,410,000 shares $25.23 million +5.3%N/A5.3 $7.40The Weight Loss Pill That Could Disrupt a $32 Billion Industry (Ad)A revolutionary new weight loss pill is about to send shockwaves through the plus-size clothing market. Analysts are calling it the "King Kong" of diet drugs after amazing clinical trial results.Don't miss out on the "next Ozempic" >>> FULC Short Interest - Frequently Asked Questions What is Fulcrum Therapeutics' current short interest? Short interest is the volume of Fulcrum Therapeutics shares that have been sold short but have not yet been covered or closed out. As of April 15th, investors have sold 2,530,000 shares of FULC short. Learn More on Fulcrum Therapeutics' current short interest. What is a good short interest ratio for Fulcrum Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. FULC shares currently have a short interest ratio of 4.0. Learn More on Fulcrum Therapeutics's short interest ratio. Which institutional investors are shorting Fulcrum Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Fulcrum Therapeutics: Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Fulcrum Therapeutics' short interest increasing or decreasing? Fulcrum Therapeutics saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 2,530,000 shares, an increase of 11.9% from the previous total of 2,260,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Fulcrum Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the sector of "medical" compare to Fulcrum Therapeutics: Entrada Therapeutics, Inc. (9.71%), Theravance Biopharma, Inc. (14.72%), Acelyrin, Inc. (12.80%), Revance Therapeutics, Inc. (11.16%), PepGen Inc. (1.25%), Esperion Therapeutics, Inc. (11.04%), Neurogene Inc. (8.58%), Adlai Nortye Ltd. (0.02%), Lexicon Pharmaceuticals, Inc. (8.17%), Korro Bio, Inc. (2.58%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.70 billion), Occidental Petroleum Co. ($3.52 billion), Charter Communications, Inc. ($3.14 billion), General Motors ($2.68 billion), Coinbase Global, Inc. ($2.57 billion), Moderna, Inc. ($2.18 billion), Tractor Supply ($2.10 billion), Royal Caribbean Cruises Ltd. ($1.91 billion), TC Energy Co. ($1.90 billion), and Williams-Sonoma, Inc. ($1.78 billion). View all of the most shorted stocks. What does it mean to sell short Fulcrum Therapeutics stock? Short selling FULC is an investing strategy that aims to generate trading profit from Fulcrum Therapeutics as its price is falling. FULC shares are trading down $0.21 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Fulcrum Therapeutics? A short squeeze for Fulcrum Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of FULC, which in turn drives the price of the stock up even further. How often is Fulcrum Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including FULC, twice per month. The most recent reporting period available is April, 15 2024. More Short Interest Resources from MarketBeat Related Companies: Entrada Therapeutics Short Interest Data Theravance Biopharma Short Interest Data Acelyrin Short Interest Data Revance Therapeutics Short Interest Data PepGen Short Interest Data Esperion Therapeutics Short Interest Data Neurogene Short Interest Data Adlai Nortye Short Interest Data Lexicon Pharmaceuticals Short Interest Data Korro Bio Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:FULC) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorFidelity, Bezos, Goldman Bet Big on Tiny BiotechBehind the MarketsAI “wealth window” is closing June 25thParadigm PressElon Musk Secret Crypto Plot ExposedCrypto 101 MediaGold Set to EXPLODE!Gold Safe ExchangeShocking: One AI startup's revenue could surge 4,735%Manward PressThe #1 lithium battery stock to have on your radar in 2024!Smallcaps DailyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing